Article citationsMore>>
Dawson, S.J., Tsui, D.W., Murtaza, M., Biggs, H., Rueda, O.M., Chin, S.F., Dunning, M.J., Gale, D., Forshew, T., Mahler-Araujo, B., Rajan, S., Humphray, S., Becq, J., Halsall, D., Wallis, M., Bentley, D., Caldas, C. and Rosenfeld, N. (2013) Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. New England Journal of Medicine, 368, 1199-1209.
https://doi.org/10.1056/NEJMoa1213261
has been cited by the following article:
-
TITLE:
Detection of the PIK3CA Mutation in Circulating Tumor DNA as a Possible Predictive Indicator for Poor Prognosis of Early-Stage Breast Cancer
AUTHORS:
Ayaka Sato, Masahiko Tanabe, Yumi Tsuboi, Masako Ikemura, Keiichiro Tada, Yasuyuki Seto, Yoshinori Murakami
KEYWORDS:
Early-Stage Breast Cancer, PIK3CA, Circulating Tumor DNA, Plasma, Droplet Digital PCR
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.9 No.1,
January
26,
2018
ABSTRACT: Objectives: Circulating tumor DNA (ctDNA) is shown to provide the real-time genomic information of metastatic breast cancer. This
study elucidates the clinico-pathological significance of ctDNA in early-stage breast
cancer using the PIK3CA mutation as an indicator. Materials and Methods: Twenty-seven primary breast cancers without metastasis were surgically resected and pathologically diagnosed at the University of Tokyo Hospital, Japan. Genomic
DNA of primary tumor was extracted from formalin-fixed and paraffin-embedded
specimens. ctDNA was extracted from fresh-frozen plasma from patients. The PIK3CA mutations at E542K, E545K and H1047R were
examined by Sanger sequencing or droplet digital PCR in 27 tumors and
pre- and post-surgery plasma. Results: The PIK3CA mutations were detected in
13 (48%) of 27 primary tumors. These mutations did not significantly correlate
with specific clinico-pathological characteristics of tumors. When ctDNA was
examined, 4 (33%) of 12 cases carrying the mutated PIK3CA showed the
identical mutation in pre-surgery plasma and 2 (50%) of them showed the identical
mutations in post-surgery plasma. Interestingly, in these 2 cases in
pathological stages IIIA and IA, fractional abundance of the mutated PIK3CA alleles to the total alleles in pre-surgery ctDNA was around 1% or more
and was higher than that of the other two cases without PIK3CA mutations in
post-surgery ctDNA. Conclusions: The PIK3CA mutation in ctDNA is detectable even
in a subset of early-stage breast cancer. Furthermore, fractional abundance of
the mutated PIK3CA in pre-surgery ctDNA could provide a possible predictive
indicator for tumor burden and for choosing the appropriate adjuvant treatment
of breast cancer.
Related Articles:
-
Hervé A. N’cho, Innocent K. Kouame, Kouadio Koff, Lazare K. Kouassı, Séraphin K. Konan, Ruth Baï, Andrei Sandu, Ion Sandu
-
Koffi Sébastien Ouffoué, Moreto Salla, Denis Yapo Kicho, Dodiomon Soro, Kouhété Philippe Da, Zanahi Félix Tonzibo
-
Trazié Kevin Guessan-Bi, Kouadio Dagobert Kra, Koffi Éric Kwadjo, Konan Lucien Kouame, Mamadou Doumbia
-
Junda Lin
-
Ananda Prasad Panta, Ram Prasad Ghimire, Dinesh Panthi, Shankar Raj Pant